atients (n=161) their where no changes in the level of HbA1C (www.rxlist.com).Proposed benefits of drug: Atacand HCTAtacand HCT (Candesartan celexetil-hydrochlorothiazide) was developed for patients who were unsuccessfully treated with single antihypertensive agents. The proposed benefit is elicited by the drugs action on angiotensin II receptor antagonists, the agent that causes vasoconstriction. Additionally the second ingredient hydrochlorothiazide a diuretic reduces blood pressure by improving the kidneys ability to eliminate salt and fluid from the body (www.centerwatch.com). Research method: Atacand HCTThey were five double blind, placebo controlled trials for Candesartan celexetil hydrochlorothiazide, which we’re eight weeks to twelve weeks in duration. The combined study sample consisted of 3,037 hypertensive patients and dosage ranged from 2 to 32 mg Candesartan celexetil and from 6.25 to 25 mg hydrochlorothiazide administered once daily in several combinations (www.centerwatch.com).Results of drug research: Atacand HCTThe antihypertensive effects of Atacand was similar in men and women in patients older and younger than 65 (www.rxlist.com). Atacand HCT or the combination (Candesartan celexetil and hydrochlorothiazide) resulted in placebo adjusted decreases in sitting systolic and diastolic blood pressures between 14-18/ 8-11 mmHg at doses of 16-12.5 mg and 32-for 12.5 mg (http://nursing.medscape.com). Nursing implications: Atacand HCT Monitor blood pressure and pulse frequently during dosage adjustment and periodically throughout therapy. Monitor intake and output ratios and daily weight (www.lexilcom). Monitor frequency of prescription refills to determine compliance (J. Deglin, A. Vallerand, 1999).Nursing Diagnosis: Atacand HCTTissue perfusion, altered (indications)Knowledge deficit, related to medication regimenNoncompliance Risk for injury, fallPharmacokinetics: Diltiazem HCL ORAL80% of the oral dose is absorbed fr...
